Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

April 17, 2024

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Via Benzinga

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge ↗

April 17, 2024

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.32% to 37,678.27 while the NASDAQ fell 1.16% to 15,681.95. The...

Via Benzinga

Topics Stocks

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data ↗

April 17, 2024

Sage Therapeutics' Phase 2 study on dalzanemdor (SAGE-718) for mild cognitive impairment in Parkinson's Disease. Learn about topline results, safety, and future milestones in 2024.

Via Benzinga

Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews ↗

March 26, 2024

Via Benzinga

Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights ↗

February 28, 2024

Via Benzinga

Earnings Scheduled For February 14, 2024 ↗

February 14, 2024

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 17, 2024

Via Benzinga

Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark ↗

April 17, 2024

Safe Therapeutics emphasized it's still testing the same drug in patients with Alzheimer's and Huntington's diseases.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 17, 2024

Via Benzinga

J B Hunt Transport Reports Downbeat Earnings, Joins ASML And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 17, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Wednesday.

Via Benzinga

Topics Stocks

The Latest Analyst Ratings for Sage Therapeutics ↗

December 12, 2023

Via Benzinga

Analyst Ratings for Sage Therapeutics ↗

November 08, 2023

Via Benzinga

Why Sage Therapeutics Stock Sank Today ↗

November 07, 2023

A secondary stock sale and underwhelming quarterly results sent investors to the off-ramp.

Via The Motley Fool

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

April 17, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

April 11, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at Upcoming March Investor Conferences

February 28, 2024

From Sage Therapeutics, Inc.

Via Business Wire

These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results ↗

February 15, 2024

Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday.

Via Benzinga

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

February 14, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024

January 31, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference

January 08, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics Announces Changes to Board of Directors

January 08, 2024

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024

January 02, 2024

From Sage Therapeutics, Inc.

Via Business Wire

5 Biotech stocks tapping into unmet mental health treatment needs

December 20, 2023

Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments.

Via MarketBeat

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

December 14, 2023

From Sage Therapeutics, Inc.

Via Business Wire

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

December 14, 2023

From Biogen Inc.

Via GlobeNewswire

Sage Therapeutics to Present at Upcoming November Investor Conferences

November 08, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

November 07, 2023

Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry.

Via Benzinga

Earnings Scheduled For November 7, 2023 ↗

November 07, 2023

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.

Via Benzinga

Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress

November 07, 2023

From Sage Therapeutics, Inc.

Via Business Wire

Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

October 24, 2023

From Sage Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.